What You Should Know:
– GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions, is excited to introduce MIM Symphony HDR Prostate to support high dose-rate (HDR) brachytherapy.
– This innovative solution aims…
Continue Reading
Introduction
Lantheus Holdings, Inc., a renowned radiopharmaceutical-focused company, has made a significant stride in the cancer care sector by acquiring the global rights to Life Molecular Imaging’s RM2. This novel therapeutic and diagnostic pair targets…
The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification…
Continue Reading
Introduction
Artificial Intelligence (AI) continues to revolutionize the medical field, offering unprecedented advancements in diagnostics and treatment. A new study by Avenda Health, published in The Journal of Urology, demonstrates AI’s remarkable capability to enhance…
By Shania Kennedy
June 04, 2024 – A research team from Moffitt Cancer Center and the University of Oxford has created a deep learning framework to help personalize adaptive therapy schedules for patients with prostate cancer.
The…
What You Should Know:
– Blue Earth Diagnostics, a Bracco company and leader in innovative PET radiopharmaceuticals, announced a data-sharing agreement with Siemens Healthineers.
– This collaboration focuses on anonymized data from Blue Earth’s Phase 3…
Continue Reading
Funding worth A$6.5 million ($4 million) has been awarded to four genomics-focused research projects led by researchers from the University of Melbourne.These include a project that will establish a patient dataset of inherited retinal…
Continue Reading
What You Should Know:
– GE HealthCare, a leader in ultrasound-guided urology solutions, has announced the launch of Prostate Volume Assist (PVA).
– The AI-powered solution is designed to empower urologists with faster and more efficient…
Continue Reading
Avenda Health’s groundbreaking Unfold AI platform represents a monumental advancement in prostate cancer management, enabling unparalleled precision and personalized treatment strategies. Through sophisticated AI algorithms, Unfold AI integrates patient-specific data to generate comprehensive cancer…
Continue Reading
What You Should Know:
ArteraAI, a leader in artificial intelligence (AI)-powered cancer tests, today announced a significant achievement – the inclusion of their ArteraAI Prostate Test in the NCCN Clinical Practice Guidelines in Oncology (NCCN…
Continue Reading
